Skip to main content
Premium Trial:

Request an Annual Quote

VASTox, Alnylam, Hayashi Kasei

Premium
VASTox Changes Name to Summit Corporation
 
Summit Corporation this week announced the completion of the company’s name change from VASTox. The change in name was approved by shareholders at the company’s annual shareholder’s meeting on July 19.
 

 
Alnylam Licenses siRNA Patents to Japanese Distributor Hayashi Kasei
 
Alnylam said this week that it has granted a non-exclusive license for its Kreutzer-Limmer siRNA patents to Hayashi Kasei, an siRNA supplier in Japan and Korea.
 
Under the agreement, the Osaka, Japan-based Hayashi Kasei will be able to use the siRNAi patents to provide RNAi research products and services, Alnylam said.
 
"With approximately 30 licenses granted in the US, European, and Asian markets, including 14 with research product suppliers, we believe that the vast majority of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam's intellectual property," Alnylam COO Barry Greene said in a statement.
 
Financial terms of the agreement were not released.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.